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Abstract
Background Obesity is a well-known problem in children
with acute lymphoblastic leukemia (ALL), and it might be
the result of an excess in energy intake, reduced energy
expenditure, or both. The aim of this study is to describe
energy intake and physical activity during treatment for
ALL with intermittent dexamethasone (DEXA).
Methods Body mass index (BMI), energy intake, and
physical activity were measured in 16 ALL patients on
maintenance treatment and in 17 healthy controls. ALL
patients were measured during (“on DEXA”) and in
between (“off DEXA”) DEXA treatments.
Results In patients, the mean increase in BMI z-score was
1.4±1.1. Energy intake on DEXA was higher (2,125.9±
476.0 vs 1,775.1±426.1 kcal/24 h, p<0.05) and energy
intake off DEXA was lower (1,305.0±249.4 vs 1,775.1±
426.1 kcal/24 h, p<0.05), compared to healthy controls.
Physical activity on DEXA was lower compared to healthy
controls (30.0±3.9 vs 40.0±6.0 kcal kg−1 24 h−1, p<0.001
and 7,303.1±4,622.9 vs 13,927.2±3,822.7 steps, p<0.05).
Physical activity off DEXA was not different compared to
healthy controls.
Conclusion Weight gain in patients on ALL treatment
might be owing to increased energy intake and decreased
physical activity during treatment with DEXA.
Keywords Acute lymphoblastic leukemia .
Dexamethasone . Energy intake . Obesity . Physical activity
Introduction
Along with the gradually increasing survival rates in
childhood acute lymphoblastic leukemia (ALL), there is
growing concern about the quality of survival and the late
effects of therapy. One major problem in childhood ALL is
weight gain during treatment, resulting in obesity [5, 11].
Possible underlying mechanisms are treatment with cortico-
steroids [12], growth hormone deficiency following cranial
irradiation [7], and reduced habitual physical activity [10].
Obesity in general is caused by a sustained imbalance
between energy intake and energy expenditure. Regarding
the development of obesity during treatment of ALL, it is
not clear whether it is due to an excess in energy intake,
reduced energy expenditure, or a combination of both. The
aim of this study is to describe energy intake and physical
activity in ALL patients during and in between dexameth-
asone (DEXA) courses.
Methods
Patients were eligible if they were at least 4 years of age and if
they were in the maintenance phase of treatment for childhood
ALL with a regimen including intermittent DEXA, i.e., the
Dutch Childhood Oncology Group protocols ALL-9, ALL-10,
or ALL-relapse 1998. Dosages of DEXAwere 6mgm−2 day−1
during 14 days in ALL-9, 6 mg m−2 day−1 during 5 days
in ALL-10 medium risk, 10 mg m−2 day−1 during 14 days
in the consolidation phase of ALL-10 standard risk, and
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6 mg m−2 day−1 during 7 days in ALL-relapse’98. Courses
with DEXA alternated with courses without DEXA.
Siblings nearest in age or friends were invited to participate
as healthy controls. Participants were included if they had
no coexisting conditions relevant to energy balance, e.g.,
diabetes mellitus or physical disability. The protocol was
approved by the Ethics Committee of the University
Medical Centre Groningen. Informed written consent was
obtained from the parents of each child enrolled in the
study and from participants from the age of 12 years.
Anthropometry and body composition Standing height, to
the nearest 0.1 cm, and weight, to the nearest 0.05 kg, were
measured. Body mass index (BMI) (kg/m2) was calculated
as weight divided by height squared. BMI z scores were
calculated as (BMI−<BMI>)/SD, <BMI> and SD being the
mean BMI and standard deviation for the subject’s age and
sex, according to normative data from the Fourth Dutch
Growth Study (1997) [6]. Patients’ BMI and BMI z score at
diagnosis were calculated retrospectively using medical
records.
Energy intake and physical activity Energy intake and
physical activity were measured, concurrently, twice over
two consecutive days (i.e., overall, 4 days) “on DEXA” and
twice over two consecutive days “off DEXA” in patients and
over a random 4-day period in controls.
Energy intake was measured using a dietary diary filled
in by the parents. Food intake data were converted to
energy intake (kcal) using nutritional analysis software
(Eetmeter 2002©, The Netherlands Nutrition Centre, The
Hague) based on the database of the chemical composition
of foods in the Netherlands (NEVO, Netherlands Food
Composition chart, 2001). Physical activity was measured
by a proxy report (developed and validated for this age
group by TNO Prevention and Health, Leiden, The
Netherlands) and a pedometer. The parents reported all
their children’s activities and their durations. By multiplying
the duration of the different activities by the matching
intensity score, based on Ainsworth’s Compendium of
Physical Activities 2000, in which metabolic equivalent task
values are assigned to physical activities, we estimated the
physical activity [1]. In addition, we measured physical
activity using a pedometer, the Digiwalker SW200®. This
is a simple, inexpensive, but valid method to assess
physical activity in this age group [3]. Participants wore
the pedometers on their waists and registered the number of
daily steps.
Data analysis BMI and BMI z scores at diagnosis vs BMI
and BMI z score at the time of the study and mean daily
energy intake and physical activity on DEXA vs off DEXA
were analyzed with the paired-sample t test. Differences
between patients and controls were analyzed with analysis
of covariance to adjust for age and gender. Difference in
mean BMI z score between patients and controls was tested
by Student’s t test. p Values less than 0.05 were considered
statistically significant. All the analyses were carried out
with SPSS 12.0.2 for Windows.
Results
Nineteen patients fulfilled the inclusion criteria; the parents
of three patients refused participation because of a lack of
time. The remaining 16 patients and 17 healthy controls
entered the study. Characteristics of the participants are
summarized in Table 1. There was no difference in BMI z
score at the time of study between the patients who
participated and the patients who refused participation. As
keeping the dietary diaries and the activity reports appeared
to be very time-consuming, not all parents managed to
complete the program fully. The parents of five patients
filled in the dairies during one 2-day period on DEXA
instead of two 2-day periods and one 2-day period off-
DEXA instead of two 2-day periods. Parents of seven
healthy controls filled in the dairies during 2 or 3 days
instead of four. Mean energy intake and physical activity
were calculated for days with complete registration.
BMI and BMI z score
In patients, mean BMI and mean BMI z scores at the time
of the study were higher than at diagnosis. Mean increase in
BMI z score was 1.4±1.1. Mean BMI z score at the time of
the study was higher in patients compared to controls
(Table 1).
Energy intake and physical activity in patients:
“on steroids” vs “off steroids”
In patients, mean energy intake on DEXA was higher than
mean energy intake off DEXA. On the other hand, mean
physical activity, measured by proxy report as well as by
pedometer, was lower on DEXA compared to off DEXA
(Table 1).
Energy intake and physical activity: patients vs healthy
controls
Mean energy intake in patients on DEXA was higher
compared to that of healthy controls, but mean energy
intake in patients off DEXAwas lower compared to healthy
controls (Table 1). Mean physical activity measured by
proxy report and measured by pedometer was lower in
patients on DEXA compared to healthy controls. Mean
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physical activity measured by both proxy reports and
pedometer in patients off DEXAwas not significantly different
compared to mean physical activity in healthy controls.
Discussion
We found increased energy intake and decreased physical
activity in children with ALL during treatment with DEXA
compared to energy intake and physical activity during
treatment without DEXA. Energy intake on DEXA was
higher compared to energy intake in healthy controls.
Energy intake off DEXA was lower compared to energy
intake in healthy controls. Physical activity in ALL patients
on DEXA was lower than physical activity in healthy
controls, whereas physical activity off DEXA was not
significantly different from physical activity in healthy
controls. This is in accordance with the clinical observation
that many ALL patients are inactive and feel depressed while
on steroids. The increase in BMI z score in patients between
diagnosis and the time of the study confirms the clinical
observation of weight gain in ALL patients on treatment with
intermittent DEXA. Our study suggests that this weight gain
might be the result of increased energy intake in combination
with decreased physical activity during DEXA.
Energy intake during the maintenance phase of child-
hood ALL treatment has been studied scarcely. Reilly et al.
found an increased energy intake in ALL patients during
treatment with glucocorticoids [9]. However, they did not
compare energy intake data in patients to those in healthy
children. Bond et al. measured energy intake in ALL
patients, just before a monthly vincristine and prednisone
course. They found no differences in energy intake between
ALL patients and healthy controls [4].
We found a decreased physical activity during DEXA
courses compared to physical activity in healthy controls.
These results are in accordance with those of Aznar et al., who
also found a lower physical activity in ALL patients compared
to healthy controls [2]. As far as we know, there are no
further studies on physical activity measured in ALL patients
on treatment. Most studies on physical activity in ALL
patients were performed after completion of therapy [8, 13].
Our study has some limitations. The number of patients
was only small. However, despite the small number, our
results are supported by statistical analysis. All parents
were highly motivated to participate in the study as they all
recognized the problem of ongoing weight gain. Nevertheless,
it appeared to be quite difficult to complete all the diaries,
resulting in missing data. Finally, we did not evaluate the
possible confounding effects of the cytostatic drugs that also
form part of ALL treatment protocols.
Summarizing, we found an increased energy intake and a
decreased physical activity in ALL patients during treatment
with DEXA. The combination of high energy intake and low
physical activity may contribute to the weight gain observed
in childhood ALL patients during treatment. Therefore,
Table 1 Characteristics of patients (n=16) and controls (n=17)
Patients Controls
On steroids Off steroids
Median age (year) 5.8 (4.2–15.3) 7.1(4.0–16.7)
Median age at diagnosis (year) 4.3 (2.4–14.3) –
Median interval from diagnosis (year) 1.7 (0.4–2.2) –
Boys (n) 9 8
Girls (n) 7 9





Mean BMI (kg/m2) 18.4±3.0 17.3±3.7
Mean BMI z score 1.1±1.2 0.2±1.1*
Mean BMI at diagnosis (kg/m2) 15.6±1.6** –
Mean BMI z score at diagnosis −0.4±0.9** –
Mean change in BMI z score 1.4±1.1 –
Mean energy intake (kcal/24 h) 2,125.9±476.0***** 1,305.0±249.4****,***** 1,775.1±426.1
Mean physical activity (kcal kg−1 24 h−1) 30.0±3.9****** 38.8±6.1**** 40.0±6.0
Mean physical activity (steps/24 h) 7,303.1±4,622.9****** 11,376.7±5,471.8*** 13,927.2±3,822.7
ALL acute lymphoblastic leukemia, SR standard risk, MR medium risk, BMI body mass index
*p<0.05 vs patients at the time of study; **p<0.001 vs patients at the time of study; ***p<0.05 vs patients on steroids; ****p<0.001 vs patients
on steroids; *****p<0.05 vs controls (adjusted for age and gender); ******p<0.001 vs controls (adjusted for age and gender)
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physical activity should be encouraged, especially during
treatment with DEXA. Further studies, to confirm our
findings and to evaluate the effect of physical activity
stimulation on obesity in children with ALL, are warranted.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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